Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 1 Mendelian randomization study

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.

the SNP profile using 26 prostate cancer GWAS risk SNPs

Figure 3 Mendelian randomization (MR) using a genetic

Figure 6 Combining population-wide and high-risk strategies

Figure 1 Ischaemic stroke prevalence and mortality

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Potential interplay between physiological

Figure 1 The VEGF family of growth factors

Figure 2 Cellular pathways implicated in CIPN

Figure 5 Systems biological model of IBS

Figure 2 Pathophysiological mechanisms in LGMD

Figure 2 LocusZoom plots

Adapted with permission from Tesfaye, S. , Boulton, A. J

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Figure 2 Histopathological features in CIDP

Figure 2 Network connections of the hypothalamus

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.88 Figure 3 Common problems with the interpretation of pharmacogenetic studies in CIPN Figure 3 | Common problems with the interpretation of pharmacogenetic studies in CIPN. Several methodological drawbacks of chemotherapy-induced neuropathy (CIPN) pharmacogenetic trial design should be improved in future studies, to enable the management of CIPN to be informed by genetic associations. GWAS, genome-wide association study; SNP, single nucleotide polymorphism. Argyriou A. A. et al. (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.88